References
1. Skroumpelos A, et al. Cost-effectiveness of Fremanezumab from a Societal Perspective in England. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND23, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111391
2. Skroumpelos A, et al. Cost-Effectiveness of Fremanezumab for the Treatment of Migraine in England From a Healthcare System Perspective. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND12, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111156
3. Skroumpelos A, et al. The Cost-Effectiveness of Fremanezumab in Patients with Migraine Who Have Failed Two or More Previous Migraine Preventive Therapies From a UK Healthcare System Perspective. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND26, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111266
4. Skroumpelos A, et al. The Cost-Effectiveness of Fremanezumab in Patients With Migraine and Previous Inadequate Response to OnabotulinumtoxinA From a UK Healthcare System Perspective. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND20, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111282
5. Skroumpelos A, et al. Scenario Analyses on Major Impactful and Uncertain Inputs of the Cost-Effectiveness Model of Fremanezumab From a Healthcare System Perspective in England. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND29, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3340/111229
Rights and permissions
About this article
Cite this article
Fremanezumab a cost-effective option for migraine in the UK. PharmacoEcon Outcomes News 880, 13 (2021). https://doi.org/10.1007/s40274-021-7771-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7771-3